Morgan Stanley evaluates argenx's potential to become a dominant force in biotechnology, comparable to Vertex Pharmaceuticals' market leadership. The analysis examines the Belgian company's pipeline strength, financial performance, and competitive positioning within the immunology sector. Investors are scrutinizing whether argenx can replicate Vertex's success through innovative drug development, strategic partnerships, and sustained revenue growth in rare disease markets.

Summary auto-generated by AI from the original publisher's content. Editorial standards.